Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1461-1467

  Obermann, Ellen C ^a   Went, Philip ^b   Pehrs, Ann Christine ^b   Tzankov, Alexandar ^c   Wild, Peter J ^a   Pileri, Stefano ^d   Hofstaedter, Ferdinand ^a   Dirnhofer, Stephan ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cyclin A; Cyclin B1; Diffuse large B cell lymphoma; Immunohistochemistry; Tissue microarray

Indexed keywords

CYCLIN B; CYCLIN B1; TUMOR MARKER;

AGED; ARTICLE; B CELL LYMPHOMA; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL;

AGED; CYCLIN B; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644676952     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1461     Document Type: Article

References (43)

1. Jaffe ES, Harris NL, Stein H and Vardiman JW (eds): World Health Organization Classification of Human Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
2. Fisher RI and Shah P: Current trends in large cell lymphoma. Leukemia 17: 1948-1960, 2003. (Pubitemid 37322124)
3. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC and Golub TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74, 2002. (Pubitemid 34101731)
4. Winter JN, Andersen J, Reed JC, Krajewski S, Variakojis D, Bauer KD, Fisher RI, Gordon LI, Oken MM, Jiang S, Jeffries D and Domer P: BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 91: 1391-1398, 1998. (Pubitemid 28086893)
5. Moller MB, Nielsen O and Pedersen NT: Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. Am J Clin Pathol 115: 404-412, 2001. (Pubitemid 33694838)
6. Moller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjodt K and Pedersen NT: Frequent disruption of the RB1 pathway in diffuse large B-cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 14: 898-904, 2000. (Pubitemid 30235069)
7. Gronbaek K, Nedergaard T, Andersen MK, Thor SP, Guldberg P, Moller P, Zeuthen J, Ebbe HN, Hou-Jensen K and Ralfkiaer E: Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 12: 1266-1271, 1998. (Pubitemid 28395990)
8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000. (Pubitemid 30082188)
9. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, Le Blanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T and Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002. (Pubitemid 34651353)
10. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N and Nathwani BN: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 83: 1460-1466, 1994. (Pubitemid 24081556)
11. Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook SM, Marshall AE, Laskey RA, Miller R, Arends MJ and Coleman N: A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 201: 187-197, 2003. (Pubitemid 37258929)
12. Hunter T and Pines J: Cyclins and cancer. Cell 66: 1071-1074, 1991. (Pubitemid 121001397)
13. Resnitzky D, Gossen M, Bujard H and Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14: 1669-1679, 1994.
14. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994. (Pubitemid 24363801)
15. Zindy F, Lamas E, Chenivesse X, Sobczak J, Wang J, Fesquet D, Henglein B and Brechot C: Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun 182: 1144-1154, 1992.
16. Bertoni F, Zucca E and Cavalli F: Mantle cell lymphoma. Curr OpinHematol 11: 411-418, 2004. (Pubitemid 39491435)
17. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP and Zittoun R: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85: 2870-2876, 1995.
18. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C and Pirker R: Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8: 729-733, 2002. (Pubitemid 34742101)
19. Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL and Kuehl M: Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98: 217-223, 2001.
20. Czader M, Mazur J, Pettersson M, Liliemark J, Stromberg M, Christensson B, Tribukait B, Auer G, Ost A and Porwit A: Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer 77: 1180-1188, 1996. (Pubitemid 26080911)
21. Bjorck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Bjorkholm M, Borrebaeck CA, Porwit-MacDonald A and Nordenskjold M: High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105: 2908-2915, 2005. (Pubitemid 40446285)
22. Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, Bierman PJ, Bast MA, Daley DT and Armitage JO: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85: 3671-3678, 1995.
23. Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L and Batista N: Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 18: 15-22, 2001. (Pubitemid 32906732)
24. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S and Sauter G: Cyclin E overexpression and amplification in human tumours. J Pathol 200: 375-382, 2003. (Pubitemid 36827312)
25. Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, Pileri S and Dirnhofer S: Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 16: 1141-1147, 2003. (Pubitemid 37414209)
26. Went P, Dellas T, Bourgau C, Maurer R, Augustin F, Tzankov A and Dirnhofer S: Expression profile and prognostic significance of CD24, p53 and p21 in lymphomas. A tissue microarray study of over 600 non-Hodgkin lymphomas. Dtsch Med Wochenschr 129: 2094-2099, 2004. (Pubitemid 39381881)
27. Jin YH and Park C: Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications. J Korean Med Sci 17: 322-327, 2002.
28. Endl E and Gerdes J: The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257: 231-237, 2000. (Pubitemid 30390473)
29. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000. (Pubitemid 30054364)
30. Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ and Coleman N: A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 90: 1583-1590, 2004. (Pubitemid 38648242)
31. Bubendorf L, Nocito A, Moch H and Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195: 72-79, 2001.
32. Zinzani PL, Dirnhofer S, Sabattini E, Alinari L, Piccaluga PP, Stefoni V, Tani M, Musuraca G, Marchi E, Falini B, Baccarani M and Pileri SA: Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 90: 341-347, 2005. (Pubitemid 40388984)
33. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S and El-Serafi M: Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 4: 22, 2004.
34. Bukholm IR, Bukholm G, Holm R and Nesland JM: Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol 56: 368-373, 2003. (Pubitemid 36566823)
35. Wolowiec D, Berger F, Ffrench P, Bryon PA and Ffrench M: CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. Leuk Lymphoma 35: 147-157, 1999. (Pubitemid 29454412)
36. Girard F, Strausfeld U, Fernandez A and Lamb NJ: Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67: 1169-1179, 1991. (Pubitemid 121001529)
37. Fotedar A, Cannella D, Fitzgerald P, Rousselle T, Gupta S, Doree M and Fotedar R: Role for cyclin A-dependent kinase in DNA replication in human S phase cell extracts. J Biol Chem 271: 31627-31637, 1996. (Pubitemid 26408625)
38. Yin XY, Grove L, Datta NS, Katula K, Long MW and Prochownik EV: Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res 61: 6487-6493, 2001. (Pubitemid 32785287)
39. Shiohara S, Shiozawa T, Miyamoto T, Feng YZ, Kashima H, Kurai M, Suzuki A and Konishi I: Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch 446: 626-633, 2005. (Pubitemid 40922268)
40. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, Alameda F and Sanchez-Cespedes M: Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 10: 8486-8492, 2004. (Pubitemid 40053414)
41. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M and Matsuura N: Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59: 68-74, 2000. (Pubitemid 30435839)
42. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60: 4000-4004, 2000. (Pubitemid 30636572)
43. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Tsanou E, Grepi C, Galani V and Kanavaros P: Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol 17: 847-856, 2004. (Pubitemid 38843368)